Stock 471A ATYR PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages aTyr Pharma, Inc. Deutsche Boerse AG

Equities

471A

US0021202025

Market Closed - Deutsche Boerse AG
Other stock markets
 12:36:19 07/06/2024 pm IST 		5-day change 1st Jan Change
1.67 EUR +1.83% Intraday chart for aTyr Pharma, Inc. +9.87% +29.46%
05/06 ATyr Pharma, Inc. will Change its Ticker to ATYR. from LIFE CI
14/05 ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ATyr Pharma, Inc. will Change its Ticker to ATYR. from LIFE
ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect?? Study of Efzofitimod in Patients with Ssc-Ild
Top Premarket Gainers
Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes
ATyr Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
ATyr Pharma's Efzofitimod Gets Orphan Drug Label from European Commission for Systemic Sclerosis
Insider Buy: aTYR Pharma
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
ATyr Pharma Publishes First Peer-Reviewed Paper on Efzofitimod as Potential Therapy for Pulmonary Sarcoidosis
ATyr Pharma, Inc. to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate Atyr0101 At Keystone Symposia on Fibrosis Pathogenesis and Resolution
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
ATyr Pharma, Inc. Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application
ATyr Pharma to Obtain $10 Million in Milestone Payment After Partner Starts Dosing Patients in Lung Disease Study in Japan
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATYR Stock
  4. 471A Stock
  5. News aTyr Pharma, Inc.
  6. Other languages